Amanda Nizam, MD
Amanda Nizam, MD, is a GU medical oncologist at the Cleveland Clinic, specialized in treating bladder, kidney, and prostate cancer.
Articles by Amanda Nizam, MD
Drs. Koshkin and Nizam discuss how a longer treatment-free interval may predict benefit from pembrolizumab rechallenge.
Drs. Koshkin and Nizam break down recent research on pembro in patients with la/mUC who responded to first-course pembro.
Dr. Nizam touched on her study of real-world safety of first-line therapies for locally advanced or metastatic UC in the US.
Drs. Ghatalia and Nizam break down in detail the RETAIN-2 study, a phase 2 trial of risk enabled therapy for MIBC.
Drs. Nizam and Packiam review the findings from a study on AI-powered biomarkers to aid NMIBC diagnosis and treatment.
Dr. Koshkin highlights phase 2 data on futibatinib plus pembrolizumab for advanced urothelial carcinoma.
Drs. Tawagi, Nizam encourage earlier monitoring and intervention to mitigate EV-induced neuropathy in certain patients.
Dr. Grande discusses the importance of durvalumab for shifting the MIBC treatment landscape.
Dr. Jensen highlights the single-arm trial design and TOMBOLA's use of ctDNA.
Dr. Galsky discusses the value of HER2 status and the promising 75% ORR from the phase 2 trial.
Drs. Grande, Nizam continue their conversation on EVITA, including the personalization of treatment to predict toxicity.
Drs. Grande and Nizam discuss the development of criteria for identifying mUC patients ineligible for EV/pembro.
Drs. Gupta and Nizam discuss the findings from the patient-reported outcomes in the EV-302 trial for urothelial carcinoma.
Drs. van der Heijden and Nizam weigh the EV-302 subanalyses of the cisplatin-eligible, -ineligible populations.
Drs. Cigliola and Nizam discuss the implications of the reported SURE-01/02 study interim results.
Drs. Galsky and Nizam spotlight a phase 3 study of disitamab vedotin for la/mUC that expresses HER2.
Drs. Matthew Galsky and Amanda Nizam break down the latest data subanalysis from the CheckMate 901 trial.
Drs. Koshkin and Nizam discuss the trastuzumab deruxtecan FDA approval and the DESTINY-PanTumor02 clinical trial.
The outcomes related to sacituzumab govitecan for patients with variant histologies are highlighted.
The potential for sequencing erdafitinib and EV for patients with FGFR2/3-altered disease is considered.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.